Now I have a thorough understanding of the paper. Let me compose the final review.

## Summary

This paper introduces SUFO, a systematic framework integrating Supervised probing, Unsupervised similarity analysis (RSA), Feature dynamics (PCA), and Outlier analysis to interpret fine-tuned transformer feature spaces for clinical decision-making. The authors conduct a case study on pathology report classification with five 110M-parameter transformers (BERT, TNLR, BioBERT, Clinical BioBERT, PubMedBERT), revealing: (1) domain-specific PubMedBERT overfits to minority classes under imbalance despite having the richest pre-trained features; (2) in-domain pre-training accelerates feature disambiguation; (3) fine-tuning induces feature space sparsification that enables outlier analysis. Findings are partially validated on MedNLI.

## Strengths

- **SUFO integrates multiple complementary analysis techniques into a systematic pipeline, going beyond prior isolated feature analyses.** The paper explicitly builds on probing, RSA, PCA, and outlier analysis from prior work (citations to tenney2018what, saphra-lopez-2019, what-happen-bert-ft, bert-qa-lp) and combines them into a single interpretability framework aimed at practitioner-facing questions. This integration — and the explicit mapping of each component to a different trust/safety question — is a novel methodological contribution over past work that applies these techniques in isolation.

- **Counterintuitive finding about domain-specific vs. mixed-domain models under class imbalance, supported by converging evidence from fine-tuning, probing, and cross-dataset validation.** Table 1 shows PubMedBERT performing poorly on Path-PG (F1=0.770±0.12) versus Clinical BioBERT (0.959±0.03), while Table 2 shows PubMedBERT has the best pre-trained probing features (0.494 avg). The MedNLI simulation (Section 3.1) corroborates the pattern: PubMedBERT outperforms Clinical BioBERT on balanced data but underperforms on highly imbalanced data. This convergence of evidence from multiple SUFO components is the paper's most striking result.

- **Domain-expert-validated outlier analysis that reveals clinically meaningful differences between models.** Five specific outlier modes are identified (wrongly labeled, inconsistent, multiple sources, truncated/not reported, boundary), and Clinical BioBERT and PubMedBERT are shown to flag more instances of missing/unreported medical information than general-domain models. The involvement of a clinician (urologist) grounds the analysis in real clinical interpretation needs.

## Weaknesses

### Fatal
None.

### Major

- **The central claim that PubMedBERT "overfits" to minority classes lacks per-class metrics, training curves, or mechanistic evidence to distinguish overfitting from alternative explanations.** The paper attributes PubMedBERT's poor Path-PG F1 (0.770) to overfitting, but provides no per-class precision/recall for the 3% minority class (Gleason grade 5), no training/validation loss curves over epochs, and no evidence that PubMedBERT's minority-class performance peaks early and degrades. Without these, competing explanations remain plausible — e.g., a fundamental incompatibility between PubMedBERT's specialized vocabulary and the pathology note sub-domain, or insufficient gradient signal for rare labels despite the weighted sampling mentioned in Section 3. The feature dynamics observation ("mixing of classes in PubMedBERT's scatterplots") is suggestive but also qualitative. The paper's headline empirical finding would be substantially strengthened by standard overfitting diagnostics.

### Minor

- **The claim that in-domain pre-training accelerates feature disambiguation (epoch 6 vs. epoch 9) relies entirely on visual inspection of PCA plots, with no quantitative separability metric.** The paper states this temporal difference as a finding (Section 4.2, "Results") but provides no Silhouette scores, Davies–Bouldin indices, k-NN separability, or any other quantitative measure computed over training checkpoints. The reader cannot evaluate whether this timing difference is robust across runs or an artifact of the specific PCA projection.

- **The MedNLI validation only compares two of the five models (PubMedBERT and Clinical BioBERT), limiting the generalizability claim.** The paper states it "validate[s] our findings on MedNLI" (abstract) and validates the overfitting pattern, but only two models are tested on the simulated splits. Testing all five on MedNLI — or at least acknowledging why the remaining three were excluded — would substantially strengthen the claim that the finding reflects a general principle about pre-training data categories rather than a PubMedBERT-specific artifact.

- **The outlier analysis clustering method is ad-hoc and not validated against standard alternatives, and the expert evaluation does not directly connect outliers to model errors.** The clustering procedure (extracting 1D intervals on PC1 and PC2 independently, then taking their Cartesian product) is motivated by scale differences across PCs, but no comparison to k-means, DBSCAN, or Gaussian mixtures is provided to justify its use. More importantly, the expert evaluation asks whether a report "would be challenging for human classification" — not whether the model actually misclassifies it. The paper then claims these outliers relate to model "failure modes" (Section 5 intro), but without checking whether outliers are enriched for actual misclassifications, this connection remains speculative.

- **Only 2 of 4 pathology tasks (Path-PG, Path-SG) use 3-class classification with minority classes; the binary tasks (Path-MS, Path-SV) have relatively mild imbalance (26%/13% minority).** The paper's most striking findings about overfitting and feature disambiguation are concentrated on Path-PG. While this is acknowledged implicitly, the scope of the empirical support for the paper's central claims is narrower than the multi-task framing suggests.

### Trivial

- The RSA interpretation of BERT's "versatility" (Section 3.1) could be read in reverse: moderate RSA change could equally mean BERT's pre-trained features are already well-suited to the task with little adjustment needed. Both readings are defensible but the paper should clarify the reasoning direction.
- The paper states "models leveraging in-domain pre-training... disambiguate faster" but then notes TNLR (general-domain) has "the most dissimilar" behavior, raising the question of whether BERT + TNLR should be treated as a homogeneous baseline group given their architectural differences.
- The TNLR confound (constrained self-attention, PMLM objective) is acknowledged but not systematically disentangled; the paper relies on the observation that TNLR's behavior is "similar to BERT."

## Nice-to-Haves

- Add per-class F1/precision/recall for minority classes (especially Gleason grade 5 in Path-PG) and training/validation loss curves to directly support the overfitting claim.
- Compute quantitative feature separability metrics (e.g., Silhouette score, k-NN accuracy) over training checkpoints to replace visual inspection for the feature disambiguation timing claim.
- Test all five models on MedNLI simulated splits to strengthen generalizability.
- Validate outlier extraction by checking whether outlier reports are statistically enriched for misclassified test examples (precision of outlier detection).
- A single concise pipeline diagram or table mapping each SUFO component to a specific practitioner question would improve usability.

## Removed Points

- *"The MedNLI simulation results are referenced but not visible in the provided text"* — This is a parser artifact; the table exists in the original submission. The substantive point (only 2 models tested) is retained in Minor weaknesses.
- *Strength: "Quantitative evidence that in-domain pre-training accelerates feature disambiguation"* — The evidence is qualitative (PCA visual inspection), not quantitative, as confirmed by the verified weakness. Rephrased in Strengths to reflect the qualitative nature of the finding.
- *"The paper does not investigate why fine-tuning degrades [PubMedBERT]"* — The paper does investigate this through probing (Table 2 shows best features before fine-tuning) and feature dynamics (class mixing in scatterplots), just not at the mechanistic depth the critic requests. The underlying concern (lack of training curves per class) is retained.
- *"The evidence rests on one task (Path-PG) in Table 1"* — Inaccurate; MedNLI validation provides cross-dataset support, though only for 2 models.

## Novel Insights

None beyond the paper's own contributions. The reviews surface important methodological gaps but do not identify unclaimed patterns in the data that the paper missed.

## Suggestions

1. For the overfitting claim, add a table with per-class recall for all five models on Path-PG (especially the minority Gleason grade 5) and show training loss curves separated by class for PubMedBERT vs. Clinical BioBERT.
2. Replace visual inspection of PCA plots with quantitative separability metrics (e.g., k-NN accuracy on the [CLS] embedding) computed at each checkpoint for all models.
3. For the outlier analysis, compute whether outlier reports are statistically over-represented among misclassified examples in the test set; report precision of outlier detection.
4. For the MedNLI validation, either test all five models or explicitly discuss which models were excluded and why.
5. Clarify the RSA interpretation: state explicitly that "moderate reconfiguration" could reflect either (a) the pre-trained features needing little adjustment or (b) the model being versatile — and present evidence distinguishing the two.

MY FINAL SCORE: <pineapple>6.0</pineapple>
MY FINAL DECISION: <orange>Accept</orange>